NY-COTY
1.3.2024 14:31:34 CET | Business Wire | Press release
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. (NYSE: PVH), and Calvin Klein Fragrances, a division of Coty Inc. (NYSE: COTY), today unveil actor and musician Idris Elba and his wife, model and human rights activist Sabrina Elba as the faces of Calvin Klein ETERNITY AROMATIC ESSENCE, the newest addition to the ETERNITY fragrance portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301420936/en/
Calvin Klein Fragrances announces Idris and Sabrina Elba as the face of new Calvin Klein ETERNITY AROMATIC ESSENCE fragrance campaign (Photo: Business Wire)
Shot by Mert Alas, the campaign offers a fresh and impactful take on ETERNITY’s timeless dream of eternal love, capturing Idris and Sabrina in moments of intimacy set to a bespoke cover of “Fever” by FKA twigs. The striking campaign imagery is inspired by profound connection and the essence of desire, paying tribute to ETERNITY’s legacy of sensuality by partnering with an authentic couple with a deep connection to the brand. The advertising campaign will be featured globally and supported by digital, social, print, and TV.
“Calvin Klein’s ETERNITY campaigns have always shown love that was intimate and real. It’s an honor to have our romance recognized for its authenticity, and have our commitment captured in this campaign. We are excited to be a part of ETERNITY’s iconic, timeless love story,” said Idris and Sabrina jointly.
CALVIN KLEIN ETERNITY AROMATIC ESSENCE FOR MEN and FOR WOMEN are elevated and bold aromatic fragrances, connected by a unique coconut note.
ETERNITY AROMATIC ESSENCE FOR MEN is a highly contrasted aromatic gourmand, crafted by principal perfumers Daphné Bugey and Frank Voelkl of Firmenich. The fragrance opens with fresh juniper berry essence with woody and gin-like facets. At the heart, the radiance of cardamom adds a spicy quality balanced by a sweet and floral lavender note. The seductive warmth of comforting coconut adds a sexy gourmand twist.
ETERNITY AROMATIC ESSENCE FOR WOMEN is a fresh, floral gourmand, created by perfumers Véronique Nyberg and Julie Massé of Mane. The captivating composition’s powerful freshness puts a modern twist on a floral fragrance. It opens with aromatic floral hints of lavender. At the heart, a sparkling coconut water accord unveils a vibrant gourmand, contrasted by an alluring dry down of sensual woods at the base.
The fragrances’ signature bottles and outer cartons have been reimagined with elevated codes and luxurious finishes. Inspired by the vibrancy of gemstones, the scents are housed in lacquered teal green glass bottles. Maintaining the shape and silver cap of the iconic original ETERNITY fragrances, the updated packaging exudes sensuality.
About Idris and Sabrina Elba
Idris Elba is an award-winning actor, producer, director, and musician continually securing his place as one of the most versatile performers in Hollywood. In 2016, he became the first male actor to receive dual SAG awards in one evening - Outstanding Performance by a Male Actor in a Supporting Role and Outstanding Performance in a TV Movie or Miniseries.
A multi-hyphenate in every sense of the word Sabrina Elba is not only a model, entrepreneur, and UN Goodwill Ambassador for the International Fund for Agricultural Development (IFAD) but also works with various civil society orgs like Farm Africa, Conservation International, and the European board for Global Citizen, receiving accolades like the TIME100 Impact award and the Crystal Award from the World Economic Forum.
About Calvin Klein
Calvin Klein is one of the world’s leading global fashion lifestyle brands with a history of bold, non-conformist ideals that inform everything we do. Founded in New York in 1968, the brand’s minimalist and sensual aesthetic drives our approach to product design and communication, creating a canvas that offers the possibility of limitless self-expression. The Calvin Klein brands – CK Calvin Klein, Calvin Klein, Calvin Klein Jeans, Calvin Klein Underwear, and Calvin Klein Performance – are connected by the intention and purpose of elevating everyday essentials to globally iconic status. Each of the brands has a distinct identity and position in the retail landscape, providing us the opportunity to market a range of universally appealing products to domestic and international consumers with a variety of needs. Our products are underpinned by responsible design, high-quality construction, and the elimination of all unnecessary details. We strive for unique and dimensional pieces that continuously wear well and remain relevant season after season. Global retail sales of Calvin Klein products were approximately $9.3 billion in 2022.
Calvin Klein continues to solidify its position as an innovator of emerging digital platforms and modern marketing campaigns. PVH acquired Calvin Klein in 2003 and continues to oversee a focused approach to growing the brand’s worldwide relevance, presence, and long term growth.
About Coty Inc.
Founded in Paris in 1904, Coty is one of the world’s largest beauty companies with a portfolio of iconic brands across fragrance, color cosmetics, and skin and body care. We serve consumers around the world, selling prestige and mass market products in more than 125 countries and territories. Coty and our brands empower people to express themselves freely, creating their own visions of beauty; and we are committed to protecting the planet. Learn more at coty.com or on LinkedIn and Instagram.
ADVERTISING CREDITS:
Creative Direction: Calvin Klein
Campaign Videos: Mert Alas
Advertising Campaign Images: Mert Alas
EDITORIAL CREDIT:
TERNITY AROMATIC ESSENCE FOR WOMEN CALVIN KLEIN
ETERNITY AROMATIC ESSENCE FOR MEN KLEIN
SOCIAL MEDIA: #CKEternity
BRAND HANDLE: @calvinklein
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240301420936/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom